dr. lynce on remaining questions with parp inhibitors in breast cancer
Published 4 years ago • 215 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
2:23
dr. moore on unanswered questions with parp inhibitors in ovarian cancer
-
1:25
dr lynce on the prognosis of patients with inflammatory breast cancer
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
2:25
dr. naumann on unanswered questions with parp inhibitors in ovarian cancer
-
7:42
parp inhibitors in other subtypes of breast cancer
-
3:31
distinguishing between parp inhibitors in breast cancer
-
0:56
dr. levine on combos with parp inhibitors in ovarian cancer
-
1:17
dr. traina on parp inhibition in brca-mutated breast cancer
-
2:04
questions that remain regarding combination, sequencing with parp inhibitors
-
0:56
dr. muss on the role of parp inhibitors in breast cancer
-
1:16
parp inhibitors improve outcomes, qol in breast cancer
-
2:47
talave: induction talazoparib with parp inhibition in breast cancer
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?
-
2:08
dr. lorusso on parp inhibitors in triple-negative breast cancer
-
27:25
opportunities and challenges in early breast cancer: do parp inhibitors have a role?
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
1:18
dr. robson on exploratory analysis from olympiad in breast cancer
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer